CYP1B1 is an important detox enzyme that metabolizes many compounds and is important for the development of the eye. If activity is too high or too low, CYP1B1 can be at the root of a variety of problems. Read on to learn more.<\/p>\n
<\/p>\n
The enzyme CYP1B1 is one of the cytochrome P450<\/a> monooxygenases (CYPs). These are enzymes that eliminate most of the drugs and toxins<\/strong> from the human body (R<\/a>).<\/p>\n Read more about CYPs here<\/a>.<\/p>\n This enzyme metabolizes:<\/p>\n This enzyme is found in the liver, but also in various other tissues including fat, skin, breast gland, prostate, heart, blood vessels, kidney, thymus\/marrow and immune cells, breast, uterus, brain, and eyes (R<\/a>, R<\/a>, R<\/a>, R<\/a>, R<\/a>).<\/p>\n An important role of CYP1B1 is that it helps reduce oxidative stress<\/a> (R<\/a>, R<\/a>). CYP1B1 deficiency results in increased oxidative stress<\/a> in mice (R<\/a>).<\/p>\n Also, this enzyme is important for eye development (R<\/a>, R<\/a>). Many mutations in CYP1B1 cause primary congenital glaucoma (R<\/a>, R<\/a>).<\/p>\n This enzyme can protect from cancer. CYP1B1 deficient mice have more lung tumors (R<\/a>).<\/p>\n This enzyme is produced by fat tissue, and it helps increase fat uptake (R<\/a>).<\/p>\n In mice, CYP1B1 deficiency increases AMPK<\/a>, reduces obesity<\/a>, reduces blood pressure, and improves glucose<\/a> tolerance (R<\/a>, R<\/a>).<\/p>\n Furthermore, this enzyme is capable of activating a wide range of cancer-causing compounds. Increased CYP1B1 activity has been associated with a range of cancers (R<\/a>, R<\/a>).<\/p>\n CYP1B1 activity was shown to promote the growth and metastasis of non-small lung cancer cells (R<\/a>) and may promote the growth of renal cell carcinoma (kidney cancer) cells (R<\/a>).<\/p>\n More than 150 SNPs have been reported for this gene (R<\/a>, R<\/a>).<\/p>\n Many mutations of this gene are linked to primary congenital glaucoma (R<\/a>, R<\/a>).<\/p>\n rs10012<\/a> alters androgen (testosterone<\/a>) concentrations (1499 cases and 1373 controls) (R<\/a>), with the C variant being more active (R<\/a>).<\/p>\n This may explain the association of the C variant with increased disease aggressiveness in prostate cancer (1387 subjects) (R<\/a>).<\/p>\n The C variant was also associated with an increased risk of endometrial cancer (200 subjects) (R<\/a>).<\/p>\n On the other hand, the G variant was associated with urinary bladder cancer (492 subjects) (R<\/a>).<\/p>\n<\/a>CYP1B1 Function<\/strong><\/span><\/h2>\n
\n
<\/a>CYP1B1 Location<\/strong><\/span><\/h3>\n
<\/a>Beneficial Functions<\/strong><\/span><\/h2>\n
<\/a>Potentially Detrimental Functions<\/strong><\/span><\/h2>\n
<\/a>CYP1B1 Gene Polymorphisms<\/strong><\/span><\/h2>\n
<\/a>rs10012<\/span><\/h3>\n